Acknowledgements
HIV, Hepatitis
INFECTIOUS DISEASES
We thank all the participants in the ADVANCE study that made our study possible. This work was supported in part by the National Research Foundation (NRF) (Grant numbers UID113983 and UID120647 to P.S.; 128980 as scholarship to S.M.), the Wellcome Trust [grant numbers (212265/Z/18/Z), (203135/Z/16/Z) to G.M.], the National Institute of Health (grant numbers TW010559, AI077505, TR000445, and AI110527 to D.W.H.), USA Agency of Infectious Diseases (to S.S., N.C.C., W.D.F.V), Unitaid (to S.S., N.C.C. W.D.F.V), the South African Medical Research Council (to S.S., N.C.C., W.D.F.V, and PS), ViiV Healthcare (to S.S., N.C.C., and W.D.F.V), and Gilead Sciences (to S.S., N.C.C, and W.D.F.V.). S.M. was also supported through these scholarships: the University of Cape Town, Department of Medicine Fellowship, and the University of Cape Town Vice Chancellor Research Scholarship. The abstract was presented as an oral presentation at the International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2021, a virtual meeting held from 20 to 23 September 2021. (Abstract #13).